11 investors predict a colorful, if difficult, future for psychedelic startups
TechCrunch
MAY 12, 2023
Amongst these questions are actual costs of therapies, reimbursement coverage, the commercialisation strategy for psychedelic drug development companies, resource bottlenecks with the therapists’ supply and infrastructure, etc,” they told TechCrunch+. Drug development is very costly, and start-ups are having a harder time raising cash.
99 
Let's personalize your content